When the FDA published the ICH E6 R3 guideline in September of 2025, it illustrated how much clinical trials have changed over the last decade. Today’s studies are increasingly complex, often spread across multiple sites, and dependent on specialized vendors. R3 takes those realities into account by placing greater emphasis on quality by design, risk-based oversight, and sponsor accountability.

For stakeholders like sponsors and vendors, the message is clear: regulatory expectations around vendor oversight have changed. Oversight is now viewed as a continuous responsibility with direct implications for compliance, trial quality, and patient safety. Sponsors remain accountable even when work is outsourced, and vendors are expected to operate within oversight frameworks that support transparency and inspection readiness.

The ICH E6 guidelines were developed to establish a unified standard for Good Clinical Practice. Their purpose has always been to protect trial participants and ensure data integrity. But over time, the world of clinical research has outpaced that guidance.

Although the new guidance presents challenges, the transition from R2 to R3 was driven by necessity. Oversight structures that worked a decade ago no longer hold up under current operational and regulatory pressure. And the decentralized trial models that many organizations now use didn’t exist until recently.

Vendor relationships have also changed. Many sponsors now work with separate partners for monitoring, data management, imaging, labs, and patient engagement, and each of these partnerships introduces new risk. R3 takes this complexity into account and encourages stakeholders to evolve along with it.

This white paper explains how R3 differs from R2 and explores its implications for the trial lifecycle. By the time you’re finished reading, you’ll have a better understanding of the nuances and what they mean for future studies. 

Key changes in ICH E6 R3

R3 is different from R2 in several ways, but one of the most notable changes is its emphasis on quality by design. Instead of reacting to issues after they occur, sponsors are expected to identify and manage risks proactively.

The new guidance also expands on sponsor responsibilities, particularly regarding vendor oversight. Delegation of tasks is still permitted, but accountability isn’t transferred. To ensure compliance, sponsors must be able to demonstrate how vendors are selected, managed, and evaluated throughout the entire course of the trial.

R3 further clarifies the distinction between oversight and execution. Vendors can perform critical activities — such as data collection, laboratory testing, imaging analysis, or patient engagement — but sponsors have to maintain visibility into performance, quality signals, and emerging risks. The increased use of technology also affects oversight responsibilities. R3 acknowledges that digital tools can help support oversight efforts, but makes it clear they can’t replace them altogether. 

Vendor oversight in the R3 era

For many years, vendor oversight was largely transactional, but R3 reframes it as an ongoing, outcome-focused relationship. For sponsors, this has practical implications. 

Under R3:

• Contracts and quality agreements must clearly define roles, responsibilities, and escalation pathways.
• Oversight activities must occur continuously, beyond predefined milestones or audit windows. 
• Documentation is more critical than ever. 
• Sponsors must show how oversight decisions are made and how any issues are addressed.

Oversight visits and regularly scheduled visit report reviews are equally important. These activities provide insight into vendor performance and site-level execution, especially when risks arise or metrics trend in the wrong direction.

Monitoring oversight and risk management

Within the broader context of vendor oversight, ICH E6 R3 reinforces risk-based monitoring models and clarifies how oversight functions within them. Reviewing data is still important, but identifying risk and responding promptly has become equally crucial.

Sponsors are now encouraged to use structured oversight plans, performance indicators, and risk assessment frameworks. These tools support consistency while still allowing flexibility when trial conditions change. The new guidance says escalation pathways should be defined early so that performance or compliance issues can be addressed before they impact patients or data.

Trigger-based oversight visits are an example of this change in action. Instead of applying the same level of scrutiny to every vendor or site, R3 allows sponsors to focus resources where data indicate increased risk, such as missed enrollment targets or elevated data query rates. This approach aligns oversight intensity with what’s happening on the ground, ensuring resources are focused where they’re needed most. 

Quality risk management across vendors

In the past, clinical trials typically relied on a small number of vendors, but nowadays it’s common for several to operate simultaneously. This makes oversight more challenging because responsibilities can overlap, and data often flows through multiple systems or remains siloed within individual databases. 

R3 highlights the importance of harmonized oversight across vendors, including EDC providers, central labs, imaging vendors, and CRO partners. This risk-based approach encourages sponsors to prioritize oversight efforts by tiering vendors based on criticality and impact on patient safety or primary endpoints.

Governance structures are just as important. Steering committees, clinical monitoring oversight committees, and shared dashboards create forums for issue resolution and performance review. These mechanisms support alignment and reduce the likelihood that risks go unnoticed.

Even with strong governance and risk-based oversight, sponsors may face practical challenges in implementing R3-aligned programs, such as limited internal resources or complex, multi-vendor operations. Sponsors must be aware of these hurdles, as well as the opportunities that R3-aligned oversight creates.

Challenges and opportunities

Implementing an R3-aligned oversight program isn’t required by law, but it’s the right decision if you want your organization to remain competitive. That isn’t to say it’s easy. Internal resources are often limited, vendor ecosystems are challenging to manage, and global trials introduce regulatory complexity that varies from place to place. 

Despite these obstacles, R3 creates many opportunities. Sponsors can leverage niche CROs and functional service providers to supplement internal oversight capabilities. Similarly, technology platforms can help centralize performance data and support real-time decision-making. At the same time, proactive quality frameworks give sponsors the tools to anticipate issues, such as protocol deviations or missed patient visits, rather than respond to findings after the fact.

R3 guidance supports innovation, but within a structure that reinforces accountability. This approach maintains compliance without limiting new approaches to trial design and oversight.

Preparing for R3 compliance

ICH E6 R3 takes vendor oversight from a recommended practice to a necessity, emphasizing that sponsors are ultimately accountable for trial quality, patient safety, and data integrity across all vendors.

Meeting these expectations requires proactive planning, structured oversight, and a culture where compliance and quality are baked into daily operations. By applying a risk-based oversight framework and adopting the necessary tools and processes, sponsors can strengthen trial execution and reduce the risk of costly delays or findings.

If your organization is seeking additional support, partnering with a CRO or fractional service provider like Harbor Clinical can supplement internal capabilities, provide specialized expertise, and support your team during the transition to R3.

Sponsors who begin preparing now — and use trusted partners when appropriate — will be better positioned to navigate increasingly complex research environments and ensure high-quality trial outcomes. To learn more about how we can help you, visit our website and fill out a proposal request today.